CHARLOTTESVILLE, VA / ACCESSWIRE / March 25, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced today that it filed a Registration Statement on Form S-1 on March 22, 2019, to update certain information in the Registration Statement on Form S-1 that was declared effective on July 26, 2018. The update includes the information contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the Securities and Exchange Commission (SEC) on February 19, 2019.
The Company is also seeking to register 125,000 shares of common stock under the Registration Statement on Form S-1 filed on March 22, 2019, in order to fulfill a contractual obligation to a prior holder of the Company’s warrants and notes. The newly filed registration statement on Form S-1 is subject to review by the SEC before becoming effective.
”It is important to note that by the filing of this Registration Statement on Form S-1, the Company is not offering any new or additional securities,” said Joseph Truluck, Chief Financial Officer and Chief Operating Officer of Adial Pharmaceuticals. ” At this time, the Company is not seeking to raise additional capital and we believe that our current cash-on-hand meets our budget requirements for our planned Phase 3 clinical trial of AD04 for persons suffering from Alcohol Use Disorder.”
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (”AUD”). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.
Forward Looking Statements
This communication contains certain ”forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words ”believes,””expects,””anticipates,””intends,””projects,””estimates,””plans” and similar expressions or future or conditional verbs such as ”will,””should,””would,””may” and ”could” are generally forward- looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the effectiveness of the Registration Statement on Form S-1 filed on March 22, 2019 . Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, the timing of the effectiveness of the Registration Statement on Form S-1 filed on March 22, 2019, the timing of the commencement of a Phase 3 clinical trial and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our registration statement on Form S-1 that we have filed with the SEC and the final prospectus and our Current Report on Form 10-K for the period ended December 31, 2018. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Crescendo Communications, LLC
Email: [email protected]
SOURCE: Adial Pharmaceuticals, Inc.
View source version on accesswire.com: